Clinical Trial Update: Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing pembrolizumab plus epacadostat versus pembrolizumab plus placebo in recurrent or progressive metastatic urothelial carcinoma completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Epacadostat (epacadostat)
• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: Incyte Corporation | Conditions: UC (Urothelial Cancer) | Phase 3 | Status: COMPLETED | Results posted: 2019-08-28